{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:54:55Z","timestamp":1790398495387,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyloid-\u03b2 (A\u03b2) PET is an established predictor of conversion from mild cognitive impairment (MCI) to Alzheimer\u2019s dementia (AD). We compared three PET (including an approach based on voxel-wise Cox regression) and one cerebrospinal fluid (CSF) outcome measures in their predictive power.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Datasets were retrieved from the ADNI database. In a training dataset (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009159), voxel-wise Cox regression and principal component analyses were used to identify conversion-related regions (Cox-VOI and AD conversion-related pattern (ADCRP), respectively). In a test dataset (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009129), the predictive value of mean normalized\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetapir uptake (SUVR) in AD-typical brain regions (composite SUVR) or the Cox-VOI and the pattern expression score (PES) of ADCRP and CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      as predictors were compared by Cox models (corrected for age and sex).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All four A\u03b2 measures were significant predictors (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Prediction accuracies (Harrell\u2019s\n                      <jats:italic>c<\/jats:italic>\n                      ) showed step-wise significant increases from Cox-SUVR (\n                      <jats:italic>c<\/jats:italic>\n                      \u2009=\u20090.71; HR\u2009=\u20091.84 per\n                      <jats:italic>Z<\/jats:italic>\n                      -score increase), composite SUVR (\n                      <jats:italic>c<\/jats:italic>\n                      \u2009=\u20090.73; HR\u2009=\u20092.18), CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      (\n                      <jats:italic>c<\/jats:italic>\n                      \u2009=\u20090.75; HR\u2009=\u20093.89) to PES (\n                      <jats:italic>c<\/jats:italic>\n                      \u2009=\u20090.77; HR\u2009=\u20092.71).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The PES of ADCRP is the most predictive A\u03b2 PET outcome measure, comparable to CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      , with a slight but statistically significant advantage.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00721-3","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:45:47Z","timestamp":1605807947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer\u2019s dementia: a comparison of methods"],"prefix":"10.1186","volume":"12","author":[{"name":"for the Alzheimer Disease Neuroimaging Initiative","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-0449","authenticated-orcid":false,"given":"Arnd","family":"S\u00f6rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganna","family":"Blazhenets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Tobias","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Frings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"issue":"4","key":"721_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362 Available from: https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"721_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","volume":"72","author":"S Schreiber","year":"2015","unstructured":"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ. Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. JAMA Neurol. 2015;72(10):1183 Available from: https:\/\/doi.org\/10.1001\/jamaneurol.2015.1633.","journal-title":"JAMA Neurol"},{"issue":"2","key":"721_CR3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.115.163717","volume":"57","author":"T Grimmer","year":"2016","unstructured":"Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Forster S, Forstl H, et al. Visual versus fully automated analyses of 18F-FDG and amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment. J Nucl Med. 2016;57(2):204\u20137.","journal-title":"J Nucl Med."},{"key":"721_CR4","doi-asserted-by":"crossref","unstructured":"Frings L, Hellwig S, Bormann T, Spehl TS, Buchert R, Meyer PT. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer\u2019s dementia in a memory clinic population. Eur J Nucl Med Mol Imaging. 2018; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29546632%0A; http:\/\/link.springer.com\/10.1007\/s00259-018-3983-6.","DOI":"10.1007\/s00259-018-3983-6"},{"issue":"1","key":"721_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neurobiolaging.2013.06.018","volume":"35","author":"PT Trzepacz","year":"2014","unstructured":"Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, et al. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer\u2019s dementia. Neurobiol Aging. 2014;35(1):143\u201351 Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458013002790.","journal-title":"Neurobiol Aging"},{"key":"721_CR6","doi-asserted-by":"crossref","unstructured":"Blazhenets G, Ma Y, S\u00f6rensen A, Schiller F, R\u00fccker G, Eidelberg D, et al. Predictive value of 18 F-florbetapir and 18\u2009F-FDG PET for conversion from mild cognitive impairment to Alzheimer dementia. J Nucl Med. 2019;jnumed.119.230797. Available from: http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.230797.","DOI":"10.2967\/jnumed.119.230797"},{"key":"721_CR7","unstructured":"S\u00f6rensen A, Blazhenets G, R\u00fccker G, Schiller F, Meyer PT, Frings L. Prognosis of conversion of mild cognitive impairment to Alzheimer\u2019s dementia by voxel-wise Cox regression based on FDG PET data. NeuroImage Clin. 2018;101,637. [cited 2018 Dec 11]Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213158218303851?via%3Dihub."},{"key":"721_CR8","doi-asserted-by":"crossref","unstructured":"Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58(3):373\u20139. [cited 2020 Jan 16] Available from: http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/archneur.58.3.373.","DOI":"10.1001\/archneur.58.3.373"},{"issue":"1\u20132","key":"721_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000353442","volume":"36","author":"M Nutu","year":"2013","unstructured":"Nutu M, Zetterberg H, Londos E, Minthon L, N\u00e4gga K, Blennow K, et al. Evaluation of the cerebrospinal fluid amyloid-\u03b21-42\/amyloid-\u03b21-40 ratio measured by alpha-LISA to distinguish Alzheimer\u2019s disease from other dementia disorders. Dement Geriatr Cogn Disord. 2013;36(1\u20132):99\u2013110 [cited 2020 Jan 16]Available from: https:\/\/www.karger.com\/Article\/FullText\/353442.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"721_CR10","doi-asserted-by":"crossref","unstructured":"Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid-\u03b2 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s disease: validation of two novel assays. J Alzheimer\u2019s Dis. 2014;43(1):183\u201391. [cited 2020 Jan 16] Available from: https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-140771.","DOI":"10.3233\/JAD-140771"},{"issue":"May 2016","key":"721_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pscychresns.2016.10.011","volume":"265","author":"CG Schipke","year":"2017","unstructured":"Schipke CG, Koglin N, Bullich S, Joachim LK, Haas B, Seibyl J, et al. Correlation of florbetaben PET imaging and the amyloid peptide A\u00df42 in cerebrospinal fluid. Psychiatry Res Neuroimaging. 2017;265(May 2016):98\u2013101 Available from: https:\/\/doi.org\/10.1016\/j.pscychresns.2016.10.011.","journal-title":"Psychiatry Res Neuroimaging."},{"issue":"14","key":"721_CR12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85(14):1240\u20139 [cited 2020 Feb 7] Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000001991.","journal-title":"Neurology"},{"issue":"9","key":"721_CR13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendon\u00e7a A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study. Brain. 2016;139(9):2540\u201353 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/aww160.","journal-title":"Brain"},{"key":"721_CR14","doi-asserted-by":"crossref","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b2 42 in humans. Ann Neurol. 2006;59(3):512\u20139. [cited 2020 Feb 7] Available from: http:\/\/doi.wiley.com\/10.1002\/ana.20730.","DOI":"10.1002\/ana.20730"},{"issue":"6","key":"721_CR15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann Neurol. 2013;74(6):826\u201336 Available from: http:\/\/doi.wiley.com\/10.1002\/ana.23908.","journal-title":"Ann Neurol"},{"key":"721_CR16","doi-asserted-by":"crossref","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer\u2019s Dement. 2018;14(11):1470\u201381. [cited 2020 Feb 28] Available from: http:\/\/doi.wiley.com\/10.1016\/j.jalz.2018.01.010.","DOI":"10.1016\/j.jalz.2018.01.010"},{"issue":"2","key":"721_CR17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00259-019-04466-6","volume":"47","author":"MC Ramusino","year":"2020","unstructured":"Ramusino MC, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, et al. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47(2):270\u201380 [cited 2020 Feb 7] Available from: http:\/\/link.springer.com\/10.1007\/s00259-019-04466-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"721_CR18","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain. 2016;139(4):1226\u201336 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/aww015.","journal-title":"Brain"},{"issue":"3","key":"721_CR19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138(3):772\u201383 [cited 2020 Feb 7] Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awu367.","journal-title":"Brain"},{"issue":"10","key":"721_CR20","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/brain\/awv229","volume":"138","author":"L Frings","year":"2015","unstructured":"Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W, et al. Asymmetries of amyloid-\u03b2 burden and neuronal dysfunction are positively correlated in Alzheimer\u2019s disease. Brain. 2015;138(10):3089\u201399 Available from: https:\/\/academic.oup.com\/brain\/article-lookup\/doi\/10.1093\/brain\/awv229.","journal-title":"Brain"},{"issue":"4","key":"721_CR21","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.neuroimage.2010.10.025","volume":"54","author":"PG Spetsieris","year":"2011","unstructured":"Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson\u2019s disease: methodological issues. Neuroimage. 2011;54(4):2899\u2013914 [cited 2020 Jan 28]Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053811910013170.","journal-title":"Neuroimage"},{"key":"721_CR22","doi-asserted-by":"crossref","unstructured":"Jack CR, Barrio JR, Kepe V. Cerebral amyloid PET imaging in Alzheimer\u2019s disease. Acta Neuropathol. 2013;126(5):643\u201357. [cited 2020 Feb 5] Available from: http:\/\/link.springer.com\/10.1007\/s00401-013-1185-7.","DOI":"10.1007\/s00401-013-1185-7"},{"issue":"7","key":"721_CR23","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1093\/brain\/aws125","volume":"135","author":"N Villain","year":"2012","unstructured":"Villain N, Ch\u00e9telat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-\u03b2 deposition in healthy elderly, mild cognitive impairment and Alzheimer\u2019s disease: a voxelwise PiB\u2013PET longitudinal study. Brain. 2012;135(7):2126\u201339 Available from: https:\/\/doi.org\/10.1093\/brain\/aws125.","journal-title":"Brain"},{"key":"721_CR24","doi-asserted-by":"publisher","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181\u201392. Available from: https:\/\/doi.org\/10.1002\/ana.22248.","DOI":"10.1002\/ana.22248"},{"issue":"4","key":"721_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363\u201372 Available from: https:\/\/doi.org\/10.1016\/S1474-4422(10)70043-0.","journal-title":"Lancet Neurol"},{"issue":"1","key":"721_CR26","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0532-x","volume":"11","author":"A de Wilde","year":"2019","unstructured":"de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, et al. Discordant amyloid-\u03b2 PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther. 2019;11(1):78 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31511058.","journal-title":"Alzheimers Res Ther"},{"key":"721_CR27","doi-asserted-by":"publisher","unstructured":"Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R. Association of amyloid-\u03b2 CSF\/PET discordance and tau load five years later. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000010739 Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000010739.","DOI":"10.1212\/WNL.0000000000010739"},{"key":"721_CR28","doi-asserted-by":"crossref","unstructured":"Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009\/09\/16. 2009;32(10):548\u201357. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2782537\/.","DOI":"10.1016\/j.tins.2009.06.003"},{"key":"721_CR29","doi-asserted-by":"crossref","unstructured":"Spetsieris P, Ma Y, Peng S, Ko JH, Dhawan V, Tang CC, et al. Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp. 2013;(76). [cited 2020 Jan 28] Available from: http:\/\/www.jove.com\/video\/50319\/identification-disease-related-spatial-covariance-patterns-using.","DOI":"10.3791\/50319"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00721-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00721-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00721-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T18:02:07Z","timestamp":1605808927000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00721-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00721-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent, see ADNI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Meyer reports personal fees from GE and personal fees from Philips, outside the submitted work. All other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}